A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVB or Recurrent Endometrial Cancer
Eligible for screening study DCP 001
GY018 is no longer open to registration of dMMR patient population, effective August 15, 2022. Accrual of pMMR patients will continue.
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or email@example.com for additional information.